文献速递神经技术与安全MRUS

磁共振监测与定量超声介导的双标记脂质体跨越血脑屏障递送

MRI Monitoring and Quantification of Ultrasound-Mediated Delivery of Liposomes Dually Labeled with Gadolinium and Fluorophore through the Blood-Brain Barrier.
PubMed 文献 · Ultrasound Med Biol · 2019-04-19

本研究制备了钆与荧光基团双标记的两种粒径脂质体(A组77.5 nm、B组140 nm),经0.42 MPa聚焦超声联合微泡开放血脑屏障后递送,5小时后在对比增强T1加权MRI上检测到钆信号;超声照射区较未照射区MRI对比显著增强,且较小脂质体的MRI信号相对增加更明显,组织学切片中罗丹明荧光证实脂质体蓄积。

要点

  • 聚焦超声联合微泡开放血脑屏障后5小时,超声照射区较未照射区MRI对比显著增强。
  • 较小脂质体(77.5 nm)比较大利脂质体(140 nm)的MRI信号相对增加更明显。
  • 组织学切片罗丹明荧光证实MRI信号增强源于双标记脂质体蓄积。

核心结论

  • 双标记纳米载体平台可建立,聚焦超声介导的血脑屏障开放可递送该载体跨越血管屏障,MRI可用于评估纳米载体递送范围。

研究设计与样本

  • 临床前研究,制备钆与罗丹明双标记脂质体,A组粒径77.5 nm、B组140 nm,采用薄膜水化后挤出法,评估生理条件下6小时稳定性;经0.42 MPa(水中估算)超声脉冲联合微泡开放血脑屏障递送,5小时后行对比增强T1加权MRI,处死后组织学检测罗丹明荧光确认。

关键影像表现/征象

  • 超声照射区较未照射区脑组织MRI对比显著增强。
  • 较小脂质体(平均直径77.5 nm)比较大利质体(平均直径140 nm)的MRI信号相对增加更大。
  • 组织学切片中检测到罗丹明荧光,证实标记脂质体蓄积。

局限性

  • 体内血脑屏障开放递送药物的治疗评估技术尚未充分探索。
  • 当前基于MRI的治疗评估技术受到游离钆递送所致全身毒性的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Magnetic resonance image-guided focused ultrasound has emerged as a viable non-invasive technique for the treatment of central nervous system-related diseases/disorders. Application of mechanical and thermal effects associated with focused transcranial ultrasound has been studied extensively in pre-clinical models, which has paved the way for clinical trials. However, in vivo treatment evaluation techniques on drug delivery application via blood-brain barrier opening has not been fully explored. Current treatment evaluation techniques via magnetic resonance imaging are hindered by systemic toxicity resulting from free gadolinium delivery. Here we propose a novel treatment evaluation strategy to overcome limitations by (i) synthesizing liposomes that are dually labeled with gadolinium, a magnetic resonance imaging (MRI) contrast agent, and rhodamine, a fluorophore; (ii) applying a focused ultrasound (FUS)-mediated BBB opening technique to deliver the liposomes across vascular barriers, achieving local gadolinium enhancement while reducing systemic and unwanted regional toxic effects associated with free gadolinium; and (iii) utilizing the MRI modality to confirm the delivery as it is already included in the FUS treatment in clinic. Liposomes were secondarily labeled with a fluorescent marker to confirm results obtained by MRI quantification postmortem. Two different sizes, 77.5 nm (group A) and 140 nm (group B), of gadolinium- and fluorescence-labeled liposomes were fabricated using thin-film hydration followed by extrusion methods and determined their stability up to 6 h under physiologic conditions. Gadolinium signal was detected on contrast-enhanced T1-weighted MRI 5 h after the delivery of liposomes via the BBB opening approach with an ultrasound pulse of 0.42 MPa (estimate in water) combined with microbubbles. MRI contrast was enhanced significantly in sonicated regions compared with non-sonicated regions of the brain. This was due to the accumulation of labeled liposomes, which was confirmed by detection of rhodamine fluorescence in histologic sections. The relative increase in MRI signal intensity was greater for smaller liposomes (mean diameter = 77.5 nm) than larger liposomes (mean diameter = 140 nm), which suggested a greater accumulation of the smaller liposomes in the brain after ultrasound-mediated opening of the BBB. Our findings suggest that the dual-labeled nanocarrier platform can be established, the FUS-mediated BBB opening approach can be used to deliver it through vascular barriers and MRI can be used to evaluate the extent of nanocarrier delivery.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Aryal M, Papademetriou I, Zhang YZ, et al. MRI Monitoring and Quantification of Ultrasound-Mediated Delivery of Liposomes Dually Labeled with Gadolinium and Fluorophore through the Blood-Brain Barrier. Ultrasound Med Biol. 2019. PMID: 31010598. doi:10.1016/j.ultrasmedbio.2019.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。